04/24/2024 | Press release | Distributed by Public on 04/24/2024 04:26
TABLE OF CONTENTS
TABLE OF CONTENTS
| |
Page
|
|
ABOUT THIS PROSPECTUS
|
| |
S-1
|
SUMMARY
|
| |
S-2
|
THE OFFERING
|
| |
S-4
|
RISK FACTORS
|
| |
S-6
|
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
|
| |
S-8
|
USE OF PROCEEDS
|
| |
S-11
|
DILUTION
|
| |
S-12
|
DESCRIPTION OF COMMON STOCK
|
| |
S-14
|
PLAN OF DISTRIBUTION
|
| |
S-18
|
LEGAL MATTERS
|
| |
S-20
|
EXPERTS
|
| |
S-20
|
WHERE YOU CAN FIND MORE INFORMATION
|
| |
S-20
|
INCORPORATION OF CERTAIN INFORMATION BY REFERENCE
|
| |
S-21
|
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
•
|
5,733,064 shares of common stock issuable upon exercise of outstanding options pursuant to our stock incentive plans at a weighted average option exercise price of $5.58 per share as of December 31, 2023;
|
•
|
1,948,313 shares of common stock issuable upon vesting of restricted stock units outstanding under our stock incentive plans as of December 31, 2023;
|
•
|
Up to 1,998,000 shares of common stock issuable under performance stock units outstanding under our 2018 Equity Incentive Plan as of December 31, 2023 upon the satisfaction of performance criteria;
|
TABLE OF CONTENTS
•
|
4,624,977 shares of common stock issuable upon exercise of outstanding warrants as December 31, 2023: 1,571,429 of which are exercisable at an exercise price of $4.25 per share, 143,000 of which are exercisable at an exercise price of $5.38 per share, 160,548 of which are exercisable at an exercise price of $0.96 per share, and 2,750,000 shares of which are exercisable at an exercise price of $2.60 per share;
|
•
|
947,950 shares of common stock reserved for future issuance under the 2018 Equity Incentive Plan as of December 31, 2023;
|
•
|
1,000,000 shares of common stock reserved for future issuance under the 2022 Inducement Equity Incentive Plan as of December 31, 2023;
|
•
|
39,018 shares of common stock available for future purchases under our Employee Stock Purchase Plan as of December 31, 2023; and
|
•
|
Up to 214,129 commitment shares issuable to Lincoln Park Capital Fund LLC pursuant to the Purchase Agreement, dated April 22, 2022 (the "Lincoln Park Purchase Agreement"), in connection with future purchases under the Lincoln Park Purchase Agreement.
|
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
•
|
risks associated with our development work, including any delays or changes to the timing, cost and success of our product development activities and clinical trials and plans, including those relating to Anaphylm™ (epinephrine) Sublingual Film and Libervant™ (diazepam) Buccal Film;
|
•
|
risk of delays in regulatory advancement through the FDA of Anaphylm, Libervant and our other drug candidates or failure to receive FDA approval at all;
|
•
|
the risk that we may not overcome the seven-year orphan drug exclusivity granted by the FDA for the approved nasal spray product of another company in the U.S. in order for Libervant to be granted U.S. market access for any age group of patients;
|
•
|
risk of litigation brought by third parties relating to overcoming their orphan drug exclusivity of an FDA approved product should the FDA approve Libervant for U.S. market access for any age group of this epilepsy patient population;
|
•
|
risk that a competing pediatric epilepsy product of Libervant will receive FDA approval prior to the Company's receipt of FDA approval of the Libervant NDA for these epilepsy patients between two and five years of age;
|
•
|
risk in obtaining market access for Libervant for other reasons;
|
•
|
risk in obtaining market access from the FDA for our other product candidates;
|
•
|
risk inherent in commercializing a new product (including technology risks, financial risks, market risks and implementation risks and regulatory limitations);
|
•
|
risks and uncertainties concerning the revenue stream from the monetization of our royalty rights for the product KYNMOBI®, as well as the achievement of royalty targets worldwide or in any jurisdiction and certain other commercial targets required for contingent payments under the KYNMOBI® monetization transaction, and the Company may not receive any of the additional aggregate contingent payments under the monetization agreement;
|
•
|
risk of development of a sales and marketing capability for future commercialization of our product candidates;
|
•
|
risk of sufficient capital and cash resources, including access to available debt and equity financing, including under our ATM Facility and the Common Stock Purchase Agreement entered into with Lincoln Park Capital Fund, LLC on April 12, 2022, and from revenues from operations, to satisfy all of our short-term and longer-term cash requirements and other cash needs, at the times and in the amounts needed, including near-term debt amortization schedules;
|
•
|
risk of failure to satisfy all financial and other debt covenants and of any default under our debt facility;
|
•
|
short-term and long-term liquidity and cash requirements, cash funding and cash burn;
|
TABLE OF CONTENTS
•
|
risk related to government and other claims against Indivior Inc. for which we license, manufacture and sell Suboxone® and which accounts for the substantial part of our current operating revenues, including the risk related to the recent product liability multi-district litigation related to Suboxone®;
|
•
|
risks related to the outsourcing of certain operational and staff functions to third parties;
|
•
|
risk of the rate and degree of market acceptance of our product and product candidates;
|
•
|
risk of the success of any competing products including generics;
|
•
|
risk of the size and growth of our product markets;
|
•
|
risk of compliance with all FDA and other governmental and customer requirements for our manufacturing facilities;
|
•
|
risks associated with intellectual property rights and infringement claims relating to our products;
|
•
|
risk of unexpected patent developments;
|
•
|
risk of legislation and regulatory actions and changes in laws or regulations affecting our business including relating to our products and product candidates and product pricing, reimbursement or access therefor;
|
•
|
risk of loss of significant customers;
|
•
|
risks related to claims and legal proceedings including patent infringement, securities, business torts, investigative, product safety or efficacy and antitrust litigation matters;
|
•
|
risk of product recalls and withdrawals;
|
•
|
risks related to any disruptions in our information technology networks and systems, including the impact of cyberattacks;
|
•
|
risk of increased cybersecurity attacks and data accessibility disruptions due to remote working arrangements;
|
•
|
adverse developments affecting the financial services industry;
|
•
|
risks related to inflation and rising interest rates;
|
•
|
risks related to the impact of a health pandemic on our business, including with respect to our clinical trials and the site initiation, patient enrollment and timing and adequacy of those clinical trials, regulatory submissions and regulatory reviews and approvals of our product candidates, availability of pharmaceutical ingredients and other raw materials used in our products and product candidates, supply chain, manufacture and distribution of our products and product candidates;
|
•
|
risks and uncertainties related to general economic, political (including the wars in Ukraine and Israel and other acts of war and terrorism), business, industry, regulatory and market conditions and other unusual items;
|
•
|
other uncertainties affecting us including those described in the "Risk Factors" section of this prospectus, and in our most recent Annual Report on Form 10-K filed with the SEC; and
|
•
|
use of our existing cash and cash equivalents and the anticipated use of net proceeds from this offering.
|
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
Assumed offering price per share
|
| | | |
$4.140
|
|
Net tangible book value (deficit) per share as of December 31, 2023
|
| |
$(1.572)
|
| | |
Increase in net tangible book value per share attributable to new investors
|
| |
$1.455
|
| | |
As adjusted net tangible book value per share after this offering
|
| | | |
$(0.118)
|
|
Net dilution per share to new investors participating in this offering
|
| | | |
$4.258
|
•
|
5,733,064 shares of common stock issuable upon exercise of outstanding options pursuant to our stock incentive plans at a weighted average option exercise price of $5.58 per share as of December 31, 2023;
|
TABLE OF CONTENTS
•
|
1,948,313 shares of common stock issuable upon vesting of restricted stock units outstanding under our stock incentive plans as of December 31, 2023;
|
•
|
Up to 1,998,000 shares of common stock issuable under performance stock units outstanding under our 2018 Equity Incentive Plan as of December 31, 2023 upon the satisfaction of performance criteria;
|
•
|
4,624,977 shares of common stock issuable upon exercise of outstanding warrants as December 31, 2023: 1,571,429 of which are exercisable at an exercise price of $4.25 per share, 143,000 of which are exercisable at an exercise price of $5.38 per share, 160,548 of which are exercisable at an exercise price of $0.96 per share, and 2,750,000 shares of which are exercisable at an exercise price of $2.60 per share;
|
•
|
947,950 shares of common stock reserved for future issuance under the 2018 Equity Incentive Plan as of December 31, 2023;
|
•
|
1,000,000 shares of common stock reserved for future issuance under the 2022 Inducement Equity Incentive Plan as of December 31, 2023;
|
•
|
39,018 shares of common stock available for future purchases under our Employee Stock Purchase Plan as of December 31, 2023; and
|
•
|
Up to 214,129 commitment shares issuable to Lincoln Park Capital Fund LLC pursuant to the Lincoln Park Purchase Agreement, in connection with future purchases under the Lincoln Park Purchase Agreement.
|
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
•
|
our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 5, 2024;
|
•
|
our Definitive Proxy Statement on Schedule 14A, filed with the SEC on April 28, 2023 (to the extent incorporated by reference into Part III of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022);
|
•
|
our Current Reports on Form 8-K filed with the SEC on March 15, 2024, March 21, 2024, April 1, 2024 and April 22, 2024 (to the extent the information in such reports is filed and not furnished); and
|
•
|
the description of our common stock contained in our Registration Statement on Form 8-A, filed with the SEC on July 20, 2018, as the description therein has been updated and superseded by the description of our securities contained in Exhibit 4.7 to our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, as filed with the SEC on March 11, 2020.
|
TABLE OF CONTENTS